Synthesis and optimization of novel 4,4-disubstituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors
摘要:
The synthesis and SAR of a series of 4,4-disubstituted cyclohexylbenzamide inhibitors of 11 beta-HSD1 are described. Optimization rapidly led to potent, highly selective, and orally bioavailable inhibitors demonstrating efficacy in both rat and non-human primate ex vivo pharmacodynamic models. (c) 2010 Elsevier Ltd. All rights reserved.
Benzamide derivatives of formula I are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders:
wherein R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, R
7
, R
8
, and n are as defined herein.
BENZAMIDE DERIVATIVES AS MODULATORS OF 11BETA-HSD1 FOR TREATING DIABETES AND OBESITY
申请人:Amgen Inc.
公开号:EP2044004B1
公开(公告)日:2012-08-15
US8772296B2
申请人:——
公开号:US8772296B2
公开(公告)日:2014-07-08
Synthesis and optimization of novel 4,4-disubstituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors
作者:Daqing Sun、Zhulun Wang、Seb Caille、Michael DeGraffenreid、Felix Gonzalez-Lopez de Turiso、Randall Hungate、Juan C. Jaen、Ben Jiang、Lisa D. Julian、Ron Kelly、Dustin L. McMinn、Jacob Kaizerman、Yosup Rew、Athena Sudom、Hua Tu、Stefania Ursu、Nigel Walker、Maren Willcockson、Xuelei Yan、Qiuping Ye、Jay P. Powers
DOI:10.1016/j.bmcl.2010.10.129
日期:2011.1
The synthesis and SAR of a series of 4,4-disubstituted cyclohexylbenzamide inhibitors of 11 beta-HSD1 are described. Optimization rapidly led to potent, highly selective, and orally bioavailable inhibitors demonstrating efficacy in both rat and non-human primate ex vivo pharmacodynamic models. (c) 2010 Elsevier Ltd. All rights reserved.